Checkpoint Therapeutics, Inc.

NasdaqCM:CKPT Stock Report

Market Cap: US$178.2m

Checkpoint Therapeutics Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

James Oliviero

Chief executive officer

US$1.6m

Total compensation

CEO salary percentage38.7%
CEO tenure9.3yrs
CEO ownership4.7%
Management average tenureno data
Board average tenure6.3yrs

Recent management updates

Recent updates

We're A Little Worried About Checkpoint Therapeutics' (NASDAQ:CKPT) Cash Burn Rate

Sep 20
We're A Little Worried About Checkpoint Therapeutics' (NASDAQ:CKPT) Cash Burn Rate

Checkpoint: Strong Data, But Comes With Risks

Sep 08

Checkpoint Therapeutics GAAP EPS of -$0.16 in-line, revenue of $0.02M beats by $0.01M

Aug 12

Is Checkpoint Therapeutics (NASDAQ:CKPT) In A Good Position To Deliver On Growth Plans?

May 18
Is Checkpoint Therapeutics (NASDAQ:CKPT) In A Good Position To Deliver On Growth Plans?

Checkpoint Therapeutics: Potential Upside Based On Marketing Application Submissions

Apr 18

Companies Like Checkpoint Therapeutics (NASDAQ:CKPT) Are In A Position To Invest In Growth

Feb 15
Companies Like Checkpoint Therapeutics (NASDAQ:CKPT) Are In A Position To Invest In Growth

Checkpoint Therapeutics: Another Buying Opportunity Following Cosibelimab's Impressive Topline Results

Jan 28

Checkpoint Therapeutics: Pullback Provides Opportunity To Add Ahead Of Cosibelimab's Data Readout

Nov 26

Checkpoint Therapeutics (NASDAQ:CKPT) Is In A Good Position To Deliver On Growth Plans

Oct 30
Checkpoint Therapeutics (NASDAQ:CKPT) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Checkpoint Therapeutics' (NASDAQ:CKPT) Cash Burn Rate

Jul 17
We're Not Very Worried About Checkpoint Therapeutics' (NASDAQ:CKPT) Cash Burn Rate

Checkpoint Therapeutics: Amassing A Position Ahead Of Cosibelimab Data

Jul 14

Checkpoint Therapeutics (CKPT) Investor Presentation - Slideshow

Jun 21

Checkpoint surges 24% on B. Riley buy initiation, 567% upside potential

Jun 09

It's Unlikely That Checkpoint Therapeutics, Inc.'s (NASDAQ:CKPT) CEO Will See A Huge Pay Rise This Year

Jun 02
It's Unlikely That Checkpoint Therapeutics, Inc.'s (NASDAQ:CKPT) CEO Will See A Huge Pay Rise This Year

The Checkpoint Therapeutics (NASDAQ:CKPT) Share Price Is Up 141% And Shareholders Are Boasting About It

Mar 11
The Checkpoint Therapeutics (NASDAQ:CKPT) Share Price Is Up 141% And Shareholders Are Boasting About It

CEO Compensation Analysis

How has James Oliviero's remuneration changed compared to Checkpoint Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$46m

Jun 30 2024n/an/a

-US$42m

Mar 31 2024n/an/a

-US$52m

Dec 31 2023US$2mUS$636k

-US$52m

Sep 30 2023n/an/a

-US$54m

Jun 30 2023n/an/a

-US$59m

Mar 31 2023n/an/a

-US$56m

Dec 31 2022US$2mUS$594k

-US$63m

Sep 30 2022n/an/a

-US$71m

Jun 30 2022n/an/a

-US$72m

Mar 31 2022n/an/a

-US$67m

Dec 31 2021US$2mUS$540k

-US$57m

Sep 30 2021n/an/a

-US$37m

Jun 30 2021n/an/a

-US$31m

Mar 31 2021n/an/a

-US$26m

Dec 31 2020US$2mUS$515k

-US$23m

Sep 30 2020n/an/a

-US$22m

Jun 30 2020n/an/a

-US$22m

Mar 31 2020n/an/a

-US$22m

Dec 31 2019US$2mUS$480k

-US$25m

Sep 30 2019n/an/a

-US$28m

Jun 30 2019n/an/a

-US$32m

Mar 31 2019n/an/a

-US$33m

Dec 31 2018US$2mUS$450k

-US$36m

Compensation vs Market: James's total compensation ($USD1.64M) is about average for companies of similar size in the US market ($USD1.38M).

Compensation vs Earnings: James's compensation has been consistent with company performance over the past year.

CEO

James Oliviero (48 yo)

9.3yrs

Tenure

US$1,641,591

Compensation

Mr. James F. Oliviero, III, CFA has been the Chief Executive Officer and President of Checkpoint Therapeutics, Inc. since October 16, 2015 and also has been its Director since October 15, 2018. Mr. Olivier...

Board Members

NamePositionTenureCompensationOwnership
James Oliviero
President6.3yrsUS$1.64m4.7%
$ 8.4m
Michael Weiss
Chairman of the Board9.8yrsUS$110.00k0.26%
$ 455.6k
Lindsay Rosenwald
Non-Executive Director10.2yrsUS$100.00k0.30%
$ 528.6k
Wayne Marasco
Chairman of Scientific Advisory Board9.8yrsno datano data
Roy Steven Herbst
Member of Scientific Advisory Boardno datano datano data
Neil Herskowitz
Independent Director9.4yrsUS$110.00k0.28%
$ 492.1k
Christian Béchon
Independent Director6.3yrsUS$100.00k0.27%
$ 472.8k
Barry Salzman
Independent Director9yrsUS$100.00k0.28%
$ 492.1k
Bruce Johnson
Member of Scientific Advisory Board3.8yrsno datano data
F. Hodi
Member of Scientific Advisory Board3.8yrsno datano data
Emily Ruiz
Member of Scientific Advisory Board3.8yrsno datano data
David Miller
Member of Scientific Advisory Board3.8yrsno datano data

6.3yrs

Average Tenure

63.5yo

Average Age

Experienced Board: CKPT's board of directors are considered experienced (6.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/05 07:51
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Checkpoint Therapeutics, Inc. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mayank MamtaniB. Riley Securities, Inc.
Justin WalshB. Riley Securities, Inc.
Jonathan AschoffB. Riley Wealth